Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Axsome Therapeutics, Inc. (AXSM)
Last axsome therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
axsome.com
Company Research
Source: GlobeNewswire
Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY® preliminary 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively SUNOSI® preliminary 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively SYMBRAVO® preliminary 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced preliminary fourth quarter and full year 2025 net product revenues for AUVELITY, SUNOSI, and SYMBRAVO. Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue (Unaudited) Based on preliminary unaudited financial information, Axsome expects total product revenue to be appr
Show less
Read more
Impact Snapshot
Event Time:
AXSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXSM alerts
High impacting Axsome Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AXSM
News
- Axsome Therapeutics (NASDAQ:AXSM) was downgraded by analysts at Morgan Stanley from an "overweight" rating to a "reduce" rating.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
- Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
AXSM
Earnings
- 11/3/25 - Miss
AXSM
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 4
- 1/7/26 - Form 144
- AXSM's page on the SEC website